Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948741 | 1.00 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL1642104 | 0.98 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Sulfuric Acid SCHEMBL1950566 | 0.92 | CA1 (0.59) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL3442261 | 0.86 | DRD2 (0.54) | PNMTADRA2AADRA2BADRA2CMEN1 | |
| Hydrochloric Acid SCHEMBL8187018 | 0.85 | DRD2 (0.53) | PNMTADRA2AADRA2BADRA2CMEN1 | |
| SCHEMBL4551781 | 0.83 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29370265 | 0.83 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2728205 | 0.83 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL22271652 | 0.81 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL7558546 | 0.80 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179839-B2 | Acylated indanyl amines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | claimed |
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| CN-101326182-B | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | SMITHKLINE BEECHAM CORP | 2011-09-28 | — | — | CN | disclosed |
| CN-101784551-A | bicycloaniline derivative | BANYU PHARMA CO LTD | 2010-07-21 | — | — | CN | disclosed |
| WO-2009105026-A1 | COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215841-A1 | D2 Receptor Ligand-078 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| CN-101326182-A | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | CN | disclosed |
| WO-1999052857-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-21 | — | — | WO | disclosed |
| US-5968954-A | EXHIBIT SELECTIVE BINDING AFFINITY FOR 5-HYDROXYTRYPTAMINE RECEPTORS | ADIR ET COMPAGNIE (FR) | 1999-10-19 | — | — | US | disclosed |
| WO-1997006158-A1 | BICYCLIC AMIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215841-A1 | D2 Receptor Ligand-078 | TACR2, TACR1, GPR174 | PNMT 1726/4885ADRA2A 97/4885ADRA2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.